INTRODUCTION Oral formulations of 5-aminosalicylic acid (5-ASA) for treatment of ulcerative colitis have been developed to minimize absorption prior to the drug reaching the colon. In this study, we investigate the release of 5-ASA from available oral mesalamine formulations in physiologically relevant pH conditions. METHODS Release of 5-ASA from 6 mesalamine formulations (APRISO®, Salix Phar...

The objective of this study was to develop simple, precise, accurate, reproducible and economical vireodt's method for simultaneous estimation of mesalamine (MSM) and prednisolone (PRD) in combined oral dosage form. The method involved measurement of absorbance at two wavelengths, 332nm and 246nm, λmax of MSM and PRD, respectively in phosphate buffer (pH 7.4) with dimethyl formamide (DMF) as co...

Objective: The objective of the present work was to optimize a rectal suppository containing mucoadhesive pellets Mesalamine achieve local yet sustained release for once-a-day administration therapy Inflammatory Bowel Disease. Methods: Thus, involves forming mesalamine by extrusion spheronization, which were then loaded into be administered rectally. evaluated mucoadhesion strength, swelling po...

Mesalamine (5-ASA) is widely used for the treatment of ulcerative colitis, a remitting condition characterized by chronic inflammation of the colon. Knowledge about the molecular and cellular targets of 5-ASA is limited and a clear understanding of its activity in intestinal homeostasis and interference with neoplastic progression is lacking. We sought to identify molecular pathways interfered ...

BACKGROUND & AIMS Drugs used to treat patients with ulcerative colitis are not always effective because of nonspecific distribution, metabolism in the gastrointestinal tract, and side effects. We designed a nitroxide radical-containing nanoparticle (RNP(O)) that accumulates specifically in the colon to suppress inflammation and reduce the undesirable side effects of nitroxide radicals. METHOD...

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . doi:10.1093/eurheartj/ehn615 Online publish-ahead-o...

Abstract BACKGROUND Therapies for ulcerative colitis include mesalamine, immunomodulators, biologics, and small molecules. Unfortunately, patient response is not universal, efficacy can diminish with time, postulated to be from increased drug clearance, anti-drug antibodies immune mediated pathogenesis changes. Biologic combinations have been investigated producing synergistic effects extending...

Tubulointerstitial nephritis in patients with inflammatory bowel disease has been linked to the use of 5-ASA derivatives. Various aspects of this theory have been challenged with a potential role for the underlying autoimmune disorder. Steroids are the mainstay of treatment and mycophenolate mofetil might be an effective alternative. We report a patient who responded well to mycophenolate despi...